[go: up one dir, main page]

MX2022000801A - Composicion y metodo para prevenir, aliviar o tratar lesion del higado. - Google Patents

Composicion y metodo para prevenir, aliviar o tratar lesion del higado.

Info

Publication number
MX2022000801A
MX2022000801A MX2022000801A MX2022000801A MX2022000801A MX 2022000801 A MX2022000801 A MX 2022000801A MX 2022000801 A MX2022000801 A MX 2022000801A MX 2022000801 A MX2022000801 A MX 2022000801A MX 2022000801 A MX2022000801 A MX 2022000801A
Authority
MX
Mexico
Prior art keywords
preventing
composition
alleviating
liver injury
treating liver
Prior art date
Application number
MX2022000801A
Other languages
English (en)
Inventor
Gwang Pyo Ko
Bo - Ram Cho
Hyun Ju You
Won Kim
Giljae Lee
Original Assignee
Kobiolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200087105A external-priority patent/KR20210014576A/ko
Application filed by Kobiolabs Inc filed Critical Kobiolabs Inc
Priority claimed from KR1020200095361A external-priority patent/KR102395036B1/ko
Publication of MX2022000801A publication Critical patent/MX2022000801A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/26—Klebsiella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/36—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Actinomyces; from Streptomyces (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

La presente invención se relaciona a una composición para prevenir, aliviar o tratar la lesión de hígado, por ejemplo, hígado graso no alcohólico, y más específicamente, se relaciona a una composición para prevenir o tratar la lesión de hígado que comprende una cepa de Ruminococcus spp.
MX2022000801A 2019-07-30 2020-07-30 Composicion y metodo para prevenir, aliviar o tratar lesion del higado. MX2022000801A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20190092689 2019-07-30
KR1020200087105A KR20210014576A (ko) 2019-07-30 2020-07-14 비알코올성 지방간 질환의 예측 또는 진단용 키트, 및 그의 예방 또는 치료용 약학적 조성물
KR1020200095361A KR102395036B1 (ko) 2019-07-30 2020-07-30 비알코올성 지방간 질환의 예측 또는 진단용 키트, 및 진단방법
PCT/KR2020/010097 WO2021020923A1 (ko) 2019-07-30 2020-07-30 간 손상 예방, 개선, 또는 치료용 조성물 및 간 손상 예방, 개선, 또는 치료방법
KR1020200094922A KR102401535B1 (ko) 2019-07-30 2020-07-30 간 손상 예방, 개선, 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
MX2022000801A true MX2022000801A (es) 2022-02-16

Family

ID=74228956

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022000801A MX2022000801A (es) 2019-07-30 2020-07-30 Composicion y metodo para prevenir, aliviar o tratar lesion del higado.
MX2022000802A MX2022000802A (es) 2019-07-30 2020-07-30 Kit para predecir o diagnosticar enfermedad de higado graso no alcoholico, y metodo para diagnosticar enfermedad de higado graso no alcoholico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000802A MX2022000802A (es) 2019-07-30 2020-07-30 Kit para predecir o diagnosticar enfermedad de higado graso no alcoholico, y metodo para diagnosticar enfermedad de higado graso no alcoholico.

Country Status (7)

Country Link
US (2) US20220276246A1 (es)
JP (3) JP7303372B2 (es)
AU (2) AU2020320244B2 (es)
BR (2) BR112022001637A2 (es)
CA (2) CA3148434A1 (es)
MX (2) MX2022000801A (es)
WO (2) WO2021020923A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4511026A2 (en) * 2022-04-19 2025-02-26 Cedars-Sinai Medical Center Methods of treating and diagnosing fatty liver disease
CN120118807A (zh) * 2025-04-28 2025-06-10 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 一株Mediterraneibacter faeces菌株及其在缓解代谢相关脂肪性肝病中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6351328U (es) 1986-09-22 1988-04-07
WO2006117945A1 (en) 2005-04-28 2006-11-09 Kochi University Method for detecting lipid metabolism disorder, and diagnostic agent for use therein
JP4918674B2 (ja) * 2005-06-15 2012-04-18 国立大学法人 東京医科歯科大学 非アルコール性脂肪肝の治療薬のスクリーニング方法
WO2007121100A2 (en) 2006-04-13 2007-10-25 Ambrozea, Inc. Compositions and methods for producing fermentation products and residuals
AU2010224587A1 (en) 2009-03-17 2011-09-22 Axcan Pharma, Inc. Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
JP6351328B2 (ja) 2014-03-27 2018-07-04 国立大学法人広島大学 高付加価値脂質の生産方法
AU2015353465B2 (en) 2014-11-25 2021-07-29 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and GVHD
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
MX2017014787A (es) 2015-05-21 2018-05-01 Yeda Res & Dev Poblaciones bacterianas para promover la salud.
KR20180100543A (ko) 2015-10-26 2018-09-11 크레스토보 홀딩스 엘엘씨 대변 세균총 관련 요법을 위한 조성물 및 방법
CA3010505A1 (en) 2016-01-07 2017-07-13 Ascus Biosciences, Inc. Methods for improving milk production by administration of microbial consortia
US20170290889A1 (en) 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
JP2019517783A (ja) 2016-04-20 2019-06-27 ヒューマン ロンジヴィティ，インコーポレイテッド 肝疾患を検出するためのマイクロバイオーム（ｍｉｃｒｏｂｉｏｍｅ）プロファイルの使用
WO2017210147A1 (en) 2016-05-29 2017-12-07 Wei Jia Liver disease-related biomarkers and methods of use thereof
CN115154467B (zh) 2016-06-03 2024-08-23 坎莫森特里克斯公司 治疗肝纤维化的方法
JP7542946B2 (ja) 2016-09-27 2024-09-02 ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
EP3522902A1 (en) 2016-10-04 2019-08-14 Institut National de la Recherche Agronomique Use of ahr agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders
IT201600109507A1 (it) * 2016-10-28 2018-04-28 Probiotical Spa Composizione per il trattamento preventivo o curativo dei disturbi epatici
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP6799230B2 (ja) * 2017-01-12 2020-12-16 ビオフェルミン製薬株式会社 非アルコール性脂肪性肝疾患の診断方法、又は診断用キット
EP3585405A4 (en) 2017-02-23 2020-12-09 Intercept Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS CONSISTING OF A BILIARY ACID DERIVATIVE AND A MICROBIOME AS WELL AS THEIR USES
US20200360450A1 (en) 2017-08-07 2020-11-19 Finch Therapeutics, Inc. Treatment of liver disease by modulation of the microbiome
EP4410954A3 (en) 2017-12-11 2025-01-15 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
KR20210014576A (ko) 2019-07-30 2021-02-09 주식회사 고바이오랩 비알코올성 지방간 질환의 예측 또는 진단용 키트, 및 그의 예방 또는 치료용 약학적 조성물
KR20240093392A (ko) 2021-05-10 2024-06-24 마이크로바 아이피 피티와이 리미티드 질병 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
AU2020320244B2 (en) 2024-10-10
BR112022001637A2 (pt) 2022-03-22
US20220276246A1 (en) 2022-09-01
MX2022000802A (es) 2022-02-16
AU2020323825A1 (en) 2022-03-17
JP2022542944A (ja) 2022-10-07
AU2020323825B2 (en) 2024-05-09
AU2020320244A1 (en) 2022-03-17
WO2021020920A3 (ko) 2021-03-25
BR112022001602A2 (pt) 2022-03-22
WO2021020920A2 (ko) 2021-02-04
JP7499841B2 (ja) 2024-06-14
US12274718B2 (en) 2025-04-15
WO2021020923A1 (ko) 2021-02-04
US20220257669A1 (en) 2022-08-18
CA3148431A1 (en) 2021-02-04
JP2024056699A (ja) 2024-04-23
CA3148434A1 (en) 2021-02-04
JP7303372B2 (ja) 2023-07-04
JP2022542506A (ja) 2022-10-04

Similar Documents

Publication Publication Date Title
MX2021006456A (es) Composiciones que comprenden cepas bacterianas del genero megasphaera y sus usos.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12022550165A1 (en) Interleukin-2 agents and uses thereof
JOP20210060A1 (ar) معدلات لمضاد تريبسين ألفا-1
HK1254843A1 (en) Compositions comprising bacterial strains
ZA201904387B (en) Compositions and methods for treating, ameliorating and preventing h. pylori
PH12020551995A1 (en) Modulator of apol1 expression
PH12019502174A1 (en) Modulators of pcsk9 expression
MX2018003158A (es) Composicion bioactiva para mejorar la tolerancia al estres de las plantas.
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
MX2018004274A (es) Metodos y composiciones para contracciones musculares no deseadas o anormales.
WO2018127612A3 (en) Compositions comprising lespedeza plant extract
EP4005578A4 (en) COMPOSITION AND METHODS FOR PREVENTING, RELIEVING OR TREATING LIVER INJURY
MX2021001520A (es) Metodos para retardar la ocurrencia de diabetes tipo 2 de nuevo inicio y para desacelerar el progreso de y tratamiento de la diabetes tipo 2.
MX2022000801A (es) Composicion y metodo para prevenir, aliviar o tratar lesion del higado.
CR20210668A (es) Complejos macromoleculares fungicidas de ditiocarbamat
MX2021004467A (es) Productos lacteos filtrados acidos reducidos en carbohidratos.
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
CO2022004699A2 (es) Composición mejorada
MX2021004756A (es) Productos de consumo y sistemas de suministro que usan compuestos organolepticos.
WO2019098811A3 (ko) Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
MX2021006863A (es) Composiciones que comprenden cepas bacterianas de parabacteroides para tratar el cancer.
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
MX2021003598A (es) Microorganismos para la inhibicion de patogenos vegetales.
MX2018013538A (es) Productos de zumo y métodos para reducir el oscurecimiento enzimático.